Results 51 to 60 of about 31,911 (153)
CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases
Infectious diseases are still a significant cause of morbidity and mortality worldwide. Despite the progress in drug development, the occurrence of microbial resistance is still a significant concern.
Michelle Seif +2 more
doaj +1 more source
Mosaic chromosomal alterations and relation to haematological cancer in two large Danish cohorts
Summary Mosaic chromosomal alterations (mCAs) are large somatic gains, losses and copy‐neutral loss of heterozygosity identified in the peripheral blood, which represent a relatively unexplored spectrum of clonal haematopoiesis. We aimed to describe mCAs in two large Danish cohorts with extensive long‐term registry‐based follow‐up and examine ...
Cecilie Velsoe Maeng +23 more
wiley +1 more source
Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß +3 more
wiley +1 more source
Acute lymphoblastic leukemia/lymphoma, the malignant transformation of T-cell or B-cell precursors, is the most common diagnosis in pediatric oncology. Precursor T-cell acute lymphoblastic leukemia/lymphoma commonly affects adolescents, and is associated
Lingappa Appaji +5 more
doaj
Next-generation sequencing (NGS) methods have been introduced for immunoglobulin (IG)/T-cell receptor (TR) gene rearrangement analysis in acute lymphoblastic leukemia (ALL) and lymphoma (LBL).
Rabiah Fardoos +6 more
doaj +1 more source
Integrated Engineering of CAR‐T Cells for Solid Tumours
Solid tumours pose multifactorial barriers including antigen heterogeneity, immunosuppressive microenvironment, and poor T‐cell trafficking, limiting CAR‐T efficacy compared to hematologic malignancies. Integrated engineering strategies are essential, combining logic‐gated receptors for precision, metabolic‐epigenetic reprogramming for resilience, and ...
Chao Yang +5 more
wiley +1 more source
Miguel J Franquiz,1,2 Nicholas J Short2 1Baylor College of Medicine, Houston, TX, USA; 2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence: Nicholas J ShortDepartment of Leukemia, The University of ...
Franquiz MJ, Short NJ
doaj
Thymocyte selection-associated high-mobility group box (TOX) is a DNA-binding factor that is able to regulate transcription by modifying local chromatin structure and modulating the formation of multi-protein complexes.
Lorena Maestre +11 more
doaj +1 more source
Case Report: T‐Lymphoblastic Leukemia in a Dog With Erythrophagia
ABSTRACT A 2‐year‐old male German Shepherd dog was presented with progressive weight loss, lethargy, and hyporexia. Hematologic analysis revealed a moderate macrocytic normochromic anemia and moderate thrombocytopenia. Additionally, a pronounced leukocytosis was observed, characterized by 33% large lymphoid cells, marked neutrophilia with a significant
Francisca B. Lang +7 more
wiley +1 more source
ObjectiveTo investigate the genomic signatures and prognosis of advanced-stage T cell lymphoblastic lymphoma (T-LBL) and to examine the relationship between T-LBL and T cell acute lymphoblastic leukemia (T-ALL).Methods35 Chinese T-LBL children with stage
Qinglin Liu +19 more
doaj +1 more source

